Newk’s Cares is honoring the legacy of co-founder Lori Newcomb this September during Ovarian Cancer Awareness Month with fundraising initiatives online and at the more than 100 Newk’s Eatery restaurants. Newk’s Cares is the philanthropic arm of Newk’s Eatery, the Jackson, Mississippi-based fast-casual restaurant chain. It was established in 2014, a year after Newcomb, an…
A Phase 1 trial assessing Cellectis’ investigational CAR T-cell therapy, UCARTCS1A, for the treatment of relapsed or refractory multiple myeloma has been placed on hold by the U.S. Food and Drug Administration (FDA), the company announced in a press release. The MELANI-01 study (NCT04142619) was assessing the safety and clinical activity of different doses of UCARTCS1A,…
Opdivo (nivolumab) significantly prolongs the time patients with resected esophageal or gastroesophageal junction (GEJ) cancer live without signs of disease after receiving chemoradiation therapy followed by cancer removal surgery, interim data from a Phase 3 trial show. Consistent with data from previous studies, Opdivo demonstrated a favorable safety profile in this setting. This is the…
The first participant has been dosed in the Phase 2 clinical trial IRENE, which is evaluating Incyte‘s immunotherapy retifanlimab in combination with the oncolytic virus pelareorep, by Oncolytics Biotech, as a treatment for locally advanced or metastatic triple-negative breast cancer (TNBC). The trial (NCT04445844) is currently recruiting patients at the Rutgers Cancer Institute of New…
A research team at the Thayer School of Engineering at Dartmouth received a $2.5 million grant to develop and test a device meant to help surgeons detect and remove prostate cancer cells that would otherwise be missed during surgery. The five-year grant, awarded by the National Cancer Institute, part of the National Institutes of Health, will focus…
Genetic material collected in routine cervical cancer screenings could be used to screen for ovarian cancer several years before disease symptoms are evident, possible speeding diagnosis and treatment, a study suggests. The study, “Detection of TP53 Clonal Variants in Papanicolaou Test Samples Collected up to 6 Years Prior to High-Grade Serous Epithelial Ovarian Cancer Diagnosis,” was…
Odonate Therapeutics announced that tesetaxel, together with a reduced dose of capecitabine, improved progression-free survival in metastatic breast cancer patients taking part in a Phase 3 clinical trial. Median progression-free survival (PFS) — the time lived until disease progression or death due to any cause — improved by 2.9 months on the combined therapy regimen as compared…
Throughout September for Blood Cancer Awareness Month, the Leukemia & Lymphoma Society (LLS) is asking the public to join its commitment to research, education, advocacy, and patient support. Blood cancers, including multiple myeloma, are diagnosed every three minutes in the U.S. Those who live with these conditions must also deal with challenges caused by COVID-19. “The global…
Tessa Therapeutics’ investigational CD30 CAR-T cell therapy is safe and leads to a high rate of strong and sustained responses in people with relapsed or treatment-resistant Hodgkin’s lymphoma, according to data from two Phase 1/2 trials. The trial findings were reported in “Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma,” a study published…
The Institute for Prostate Cancer Research (IPCR), a collaborative effort between the Fred Hutchinson Cancer Research Center and UW Medicine, has launched a video series of exercises especially designed to help men with prostate cancer maintain a healthy routine of physical activity. According to Lauren Brady, PhD, the postdoctoral research fellow at Fred Hutch who led…
